Intra-nasal administration of recombinant human sestrin2 (rh-sestrin2) protects from neonatal hypoxic ischemic encephalopathy in rats, by modulating the AMPK/mammalian target of rapamycin (mTOR) pathway [15]. The gene discussed is MTOR; the disease is perinatal asphyxia.